Active Pharmaceutical Ingredient Diabetes Drug Tirzepatide For Weight Loss CAS Number CAS 2023788-19-2

Tirzepatide is an advanced pharmaceutical compound developed by Eli Lilly and Company. It is classified as a dual agonist for the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual action makes Tirzepatide effective in managing type 2 diabetes and has shown significant promise in promoting weight loss. Marketed under the brand name Mounjaro, Tirzepatide has garnered attention for its efficacy and innovative mechanism of action.

Tirzepatide Peptide Powder Explained Tirzepatide peptide powder refers to the raw, unprocessed form of the Tirzepatide molecule. As a peptide, it consists of a specific sequence of amino acids that enable it to interact with the GIP and GLP-1 receptors in the body. The powder form is typically intended for research purposes, pharmaceutical manufacturing, or compounding into injectable solutions under controlled conditions.

1. Enhances Insulin Secretion: By activating both GIP and GLP-1 receptors, Tirzepatide increases insulin production in response to elevated blood glucose levels, helping to maintain better glucose control in individuals with diabetes.
2. Suppresses Glucagon Release: Tirzepatide reduces the release of glucagon, the hormone responsible for increasing blood sugar, which contributes to more stable blood glucose levels.
3. Facilitates Weight Loss: It slows gastric emptying and reduces appetite, leading to lower calorie intake and significant weight loss, making it highly effective for weight management in both diabetic and non-diabetic patients.
4. Improves Insulin Sensitivity: Tirzepatide enhances the body's responsiveness to insulin, reducing insulin resistance, a key issue in type 2 diabetes.